Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Last trade$2.37
Day change+$0.265 (+12.62%)
Day range$2.10 – $2.44
Volume3,187,687
Market cap$267M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$267.48M
Price / earnings
—
Price / book
2.29×
Price / sales
630.85×
EV / sales
606.17×
EV / EBITDA
-4.1×
Profitability
Earnings per share
-$0.46
Return on assets
-39.34%
Return on equity
-50.26%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.25×
Quick ratio
9.25×
Cash ratio
1.07×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$55.14M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NAUT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$234K
$190K
$0
$0
$0
$0
$0
$0
Cost of revenue
$24K
$15K
$0
$0
$0
$0
$0
$0
Gross profit
$210K
$175K
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$6.77M
$6.33M
$6.42M
$5.85M
$5.87M
$6.7M
$7.31M
$7.16M
Research and development
$10.18M
$9.61M
$9.71M
$9.58M
$9.61M
$10.39M
$11.54M
$12.82M
Total operating expenses
$16.95M
$15.94M
$16.12M
$15.42M
$15.47M
$17.1M
$18.84M
$19.98M
Operating income
-$16.74M
-$15.76M
-$16.12M
-$15.42M
-$15.47M
-$17.1M
-$18.84M
-$19.98M
Interest expense
$1.17M
$1.31M
$1.44M
$0
$1.9M
$2.08M
$2.23M
$0
Income before taxes
-$15.64M
-$14.47M
-$14.7M
-$13.78M
-$13.57M
-$15.03M
-$16.61M
-$17.59M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$15.64M
-$14.47M
-$14.7M
-$13.78M
-$13.57M
-$15.03M
-$16.61M
-$17.59M
Net income attributable to common shareholders
-$15.64M
-$14.47M
-$14.7M
-$13.78M
-$13.57M
-$15.03M
-$16.61M
-$17.59M
EBITDA
-$16.46M
-$15.49M
-$15.79M
-$15.02M
-$15.05M
-$16.64M
-$18.38M
-$19.46M
Basic earnings per share
-$0.12
-$0.11
-$0.12
-$0.11
-$0.11
-$0.12
-$0.13
-$0.14
Diluted earnings per share
-$0.12
-$0.11
-$0.12
-$0.11
-$0.11
-$0.12
-$0.13
-$0.14
Recent news
Company coverage with links to the original publishers.
Nautilus Biotechnology reported Q3 2026 revenue of $0.2 million and net loss of $15.6 million. The company published research in Nature Methods demonstrating its Iterative Mapping technology, shared early oncology proteoform assay data, and announced participation in an ARPA-H-funded SEEDS consortium with up to $6 million in expected funding to measure proteoforms in Alzheimer's disease and cancer research.
Nautilus Biotechnology announced it will receive up to $6 million as part of a $51.7 million ARPA-H-funded SEEDS consortium led by Buck Institute and Georgetown University. The consortium aims to predict protein misfolding and develop diagnostics and therapeutics for neurodegenerative diseases and cancer. Nautilus will deploy its Voyager Platform to measure proteoforms in Alzheimer's disease and Ewing sarcoma research.
Nautilus Biotechnology announced it will report third quarter 2026 financial results on October 27, 2026, followed by a management webcast at 5:30 a.m. PT. The company, headquartered in Seattle, is a development-stage life sciences firm focused on single-molecule protein analysis and proteomics platform technology.
Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.